Trial Profile
A genetic risk score as prognostic tool in nilotinib treated patients with chronic myeloid leukemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jan 2017
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 17 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.